| Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR A Prahallad, C Sun, S Huang, F Di Nicolantonio, R Salazar, D Zecchin, ... Nature 483 (7387), 100-103, 2012 | 2038 | 2012 |
| Regulation and Function of the PD-L1 Checkpoint C Sun, R Mezzadra, TN Schumacher Immunity 48 (3), 434-452, 2018 | 1364 | 2018 |
| Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma C Sun, L Wang, S Huang, GJJE Heynen, A Prahallad, C Robert, ... Nature 508 (7494), 118-122, 2014 | 824 | 2014 |
| Identification of CMTM6 and CMTM4 as PD-L1 protein regulators R Mezzadra, C Sun, LT Jae, R Gomez-Eerland, E De Vries, W Wu, ... Nature 549 (7670), 106-110, 2017 | 490 | 2017 |
| MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling S Huang, M Hölzel, T Knijnenburg, A Schlicker, P Roepman, U McDermott, ... Cell 151 (5), 937-950, 2012 | 456 | 2012 |
| Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3 C Sun, S Hobor, A Bertotti, D Zecchin, S Huang, F Galimi, F Cottino, ... Cell reports 7 (1), 86-93, 2014 | 325 | 2014 |
| Global gene disruption in human cells to assign genes to phenotypes by deep sequencing JE Carette, CP Guimaraes, I Wuethrich, VA Blomen, M Varadarajan, ... Nature biotechnology 29 (6), 542-546, 2011 | 238 | 2011 |
| Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies C Sun, R Bernards Trends in biochemical sciences 39 (10), 465-474, 2014 | 167 | 2014 |
| EGFR activation limits the response of liver cancer to lenvatinib H Jin, Y Shi, Y Lv, S Yuan, CFA Ramirez, C Lieftink, L Wang, S Wang, ... Nature, 1-5, 2021 | 133 | 2021 |
| RAF suppression synergizes with MEK Inhibition in KRAS Mutant Cancer Cells S Lamba, M Russo, C Sun, L Lazzari, C Cancelliere, W Grernrum, ... Cell reports 8 (5), 1475-1483, 2014 | 126 | 2014 |
| BRAF V600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts K Kemper, O Krijgsman, X Kong, P Cornelissen-Steijger, A Shahrabi, ... Cell reports 16 (1), 263-277, 2016 | 67 | 2016 |
| SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer AI Papadakis, C Sun, TA Knijnenburg, Y Xue, W Grernrum, M Hölzel, ... Cell research 25 (4), 445-458, 2015 | 61 | 2015 |
| PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition Z Gao, J Xu, Y Fan, Y Qi, S Wang, S Zhao, X Guo, H Xue, L Deng, R Zhao, ... Journal of Experimental & Clinical Cancer Research 41 (1), 223, 2022 | 10 | 2022 |
| Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer Y Guo, J Wang, B Benedict, C Yang, F van Gemert, X Ma, D Gao, H Wang, ... Genome Medicine 13 (1), 1-15, 2021 | 10 | 2021 |
| Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy H Li, Y., Yang, C., Liu, Z., Du, S., Can, S., Zhang, H., Zhang, L., Huang, X ... Molecular Cancer, 2022 | 6 | 2022 |
| CD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment X Lei, I Khatri, T de Wit, I de Rink, M Nieuwland, R Kerkhoven, ... Nature Communications 14 (1), 217, 2023 | 2 | 2023 |
| Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant L Correia, R Magno, JM Xavier, BP de Almeida, I Duarte, F Esteves, ... NPJ Breast Cancer 8 (1), 71, 2022 | 2 | 2022 |
| PHF6 functions as a tumor suppressor by recruiting methyltransferase SUV39H1 to nucleolar region and offers a novel therapeutic target for PHF6-muntant leukemia H Tsai, Y Wu, R Huang, D Su, Y Wu, X Liu, L Wang, Z Xu, Y Pang, C Sun, ... Acta Pharmaceutica Sinica B 12 (4), 1913-1927, 2022 | 1 | 2022 |
| Combinations for treatment of cancer C Sun, R Bernards US Patent 10,398,696, 2019 | | 2019 |
Rene BernardsNetherlands Cancer InstituteZweryfikowany adres z nki.nl
